Pacira BioSciences (PCRX) Gains from Investment Securities (2010 - 2026)

Pacira BioSciences' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 261.3% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.7 million (up 202.77% YoY), while the FY2025 annual figure was $5.6 million, up 2280.08% from the prior year.
• Gains from Investment Securities was $4.4 million for Q1 2026 at Pacira BioSciences, up from $143000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $12.5 million in Q2 2022 to a low of -$18.3 million in Q2 2023.
• Historically, Gains from Investment Securities has averaged $567294.1 across 5 years, with a median of $201000.0 in 2023.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities jumped 8909.35% in 2022, then plunged 1993.53% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $9.6 million in 2022, then sank by 37.82% to $6.0 million in 2023, then plunged by 102.97% to -$178000.0 in 2024, then surged by 180.34% to $143000.0 in 2025, then jumped by 2945.45% to $4.4 million in 2026.
• The last three Gains from Investment Securities figures came in at $4.4 million (Q1 2026), $143000.0 (Q4 2025), and $600000.0 (Q3 2025), per Business Quant data.